Clinical Trial Update: Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for HSK16149 Capsule in moderate-to-severe central neuropathic pain in China; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Neuropathic Pain

Drugs mentioned

• HSK16149 Capsule

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Central Neuropathic Pain | Phase 3 | Status: NOT_YET_RECRUITING